Related Experiment Video
Updated: Jun 5, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
[Study on the relation between anticancer drug-sensitivity and differentional expression of anticancer drug
Li Cai1, Bin Wang, Guangjie Sui
1Department of Internal Medicine, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang 150040, P.R.China.
Background:
In order to enhance the chemotherapeutic efficacy of advanced lung cancer and to practise the individualized treatment, it is necessary to find out the difference of anticancer drug-sensitivity in lung cancer cells. Comparing the array profile of related gene of anticancer drug-sensitivity between non-small cell lung cancer (NSCLC) cell lines and immortal human bronchial epithelial cell line BET2A, the difference of expression of related genes of anticancer drug sensitivity was detected.
Methods:
With the technique of cDNA macroarray, the different related gene proceeding of anticancer drug sensitivity expression was analysed in 6 NSCLC cell lines and BET2A cell line. RT-PCR was used to reconfirm the results.
Results:
Seventy-three genes which were differentially expressed were found from 1291 candidate genes, and there were 45 genes upregulated, and 28 genes downregulated. The results of RT-PCR were consistent with those of cDNA macroarray.
Conclusions:
The main reason of different sensitivity might be the difference of related gene of anticancer drug sensitivity expression. The results of this study provide new targets for reversing multiple drug-resistance, and they also provide experimental evidence to develop some new drugs and to realize the individualized treatment clinically.
